Noble Life Sciences Inc’s Post

This week, our CSO, Nick Stub Laursen, will be attending the 16th International Conference on Complement Therapeutics in Loutraki, Ancient Corinth, Greece.    Nick will be delivering a poster presentation on new data from Commit Biologics innovative BiCE platform which will show that Commit’s second generation #BiCE™ molecules induce superior complement-mediated cell killing compared to other technologies.   With a novel mechanism of action, Commit’s technology has the potential to be developed into best-in-class therapeutics for the treatment of cancer and autoimmune diseases.   To read more on the presentation, read the press release in the comments below!   #ComplementSystem #ImmuneSystem #Antibodies

Let's make the drug development journey faster, cheaper and more predictable. 🧪 Our team of scientists excel in combining knowledge of cancer with cutting-edge mathematics to develop sophisticated models that help speed up the complex stages of drug development, from initial pre-clinical stages to the critical clinical phases. Our approach minimises reliance on time-consuming lab work and animal studies, ensuring you get it right the first time. Ready to de-risk your drug development journey? Contact us today: https://lnkd.in/eYmCKgmX #Cancer #DrugDevelopment #VirtualTumour #Immunotherapy #CancerDrugs #CancerSimulation #CombinationTherapies #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #BioTech #StatisticalModelling #MachineLearning #Pharma #PYC

IO360 is underway! Be sure to join us for tomorrow's panel discussion, State of the IO Market, Investments, and Deals: Investment Trends in IO, featuring Lumanity's Jeff Bockman. Connect with Jeff while at the conference or and reach out to contact@lumanity.com to schedule time to meet with us. #IO360nyc #Immunology #Oncology #Pharma #Biotech #ImmunoOncology #IO360

Join us at the #FierceBiotechSummit for this featured session on September 30-Oct 1, 2024 ❗REGISTER NOW! Save up to $300 with the Advanced Rate: https://ow.ly/lXMK50SWXUY 💡What to Expect: CAR-Ts were once hailed as the future of cancer care, but by mid-2023, biotechs began shifting focus to autoimmune conditions, particularly lupus. What’s driving this change? This panel will explore strategies for biotechs navigating this new direction, whether they continue in cancer or move into autoimmune diseases. A big thank you to our Moderators & Speakers for this Panel: - Ruojing (Angus) Liu from Fierce Pharma - Jennifer Michaelson from Cullinan Therapeutics - Kristin Yarema, Ph.D. from Poseida Therapeutics, Inc. - Michael Lehmicke from Alliance for Regenerative Medicine - David Shook from Nkarta, Inc.. Stay Updated by following Fierce Life Sciences Events #FierceBiotech #Biotech #FiercePharma #Pharma #Innovation

SFBN Feed: Ahead of key meeting, FDA throws water on Peninsula company’s cancer drug hopes https://lnkd.in/g6P8vCMe Geron’s drug for blood cancer patients faces challenges in getting regulatory approval. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

We never stop learning! Many great opportunities to keep up to date with current scientific topics and methods: our partners' live webinars in May! BioPorto Diagnostics A/S about NGAL in Acute Kidney Injury Sino Biological, Inc. about single-cell in situ analysis Agrisera AB about western blot optimization Atlas Antibodies about preclinical cancer drug development Cygnus Technologies, LLC about viral clearance efficacy Vector Laboratories, Inc. about ADC performance and linker design Cusabio Technology LLC about advancement in therapeutic antibody discovery Learn more and join us: https://hubs.li/Q02wjyGV0 #webinar #lifelonglearning #diagnostics #drugdevelopment #biosciences

Today, we announced preclinical data for potential first-in-class medicines, including FHD-909, a BRM (SMARCA2) selective inhibitor, and our selective CBP degrader and selective EP300 degrader programs at the 2024 American Association for Cancer Research Annual Meeting. Learn about the data, and don't forget to register for the webcast at 5 pm ET: https://bit.ly/4aOkbZz #biotechnology #innovation #oncology #drugdevelopment #AACR24

When cytotoxic T cells want to kill cancer cells, they can make them self-destruct through a process called apoptosis, or programmed cell death. This happens in two ways: from outside the cell (extrinsic) or inside the cell (intrinsic). In the intrinsic pathway, a substance called granzymes is sent into the cancer cell by another protein called perforin. Once inside, granzymes cut a protein called BID, creating a shorter version of it. This shorter BID then starts a chain reaction that leads to the cancer cell destroying itself. Why is this important? By understanding and using these processes, scientists can develop treatments that specifically target and kill cancer cells. #pharma #research #biotech #medical #monitoring #qualityassurance #quality #drug 

In the interview with Clinical Trial Vanguard, our CEO Ping Cao discusses targeting “hard to drug” proteins that evade traditional small-molecule therapies due to their complex structures and functions BridGene, leveraging its proprietary IMTAC™ technology, seeks to innovate drug discovery by focusing on proteins essential in disease pathways yet difficult to target. This approach aims to pioneer new classes of medicines that can directly interact with and modulate protein functions, addressing significant unmet medical needs in areas like oncology and neurodegenerative diseases. Read more here: https://lnkd.in/dSHR5UU3 #DrugDiscovery #Biotechnology #ClinicalTrials #BridGeneBiosciences #IMTACPlatform #Oncology #NeurodegenerativeDiseases #InnovativeTherapies #HardToDrugProteins #PharmaceuticalResearch #MolecularBiology #ProteinTargeting #PrecisionMedicine #BioTechInnovation #MedicalResearch #CancerResearch

In my recent blog post ~ ~ ~ I couldn't help but wonder: Can a single-cell cloning process be satisfying? Check it out to learn more about how the CellRaft AIR propels Kite Pharma's cell line generation process!! 👇 #Blog #BlogPost #Education #CellLine #CellLineDevelopement #Raji #RajiCell #SuspensionCell #Research #CellTherapy #CARTCellTherapy #ProcessDevelopment #Technology #Pharma #Biotech #AssayDevelopment #Immunology #CellBasedAssay #Methods #Innovation #Satisfaction #SoSatisfying Kite Pharma